Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma

Phase 2

Active, not recruiting

• Conditions: Multiple Myeloma in Relapse; Multiple Myeloma Progression; Multiple Myeloma Stage II; Multiple Myeloma Stage I; Multiple Myeloma With Failed Remission; Multiple Myeloma Stage III
• Interventions: Drug: Rivaroxaban; Drug: ASA

• Registration Number: NCT03428373
• Lead Sponsor: Lawson Health Research Institute

Brief Summary

The intended study is designed as a a phase IV pragmatic multicenter randomized controlled clinical trial, comparing the impact of two different therapies including ASA vs. Rivaroxaban in newly diagnosed or relapsed and refractory multiple myeloma patients treated with Lenalidomide Dexamethasone (Len-Dex) combination therapy. The pilot feasibility study was conducted in preparation for this randomized controlled trial designed to assess the effect of an intervention.

Detailed Description

RithMM is a phase IV, pragmatic, multicenter, open label Canadian trial. The study started with a pilot feasibility phase where 3 centres (London, Ottawa and Halifax) enrolled 34 patients within 12 months. Utilizing a roll-over design, the full RithMM trial will require a total of 304 patients to demonstrate that rivaroxaban 10 mg daily for 6 months is superior to ASA 81 mg daily for 6 months in preventing any thromboembolic events in newly diagnosed myeloma (NDMM) and relapsed/refractory (RRMM) patients on Len-Dex -based therapy. The study will require 8 participating centres in order to be able to achieve our recruitment goal within 12 to 18 months. Patients with NDMM or RRMM receiving Len-Dex based combination therapy with or without combination with other anti-myeloma drugs will be assessed for eligibility to be enrolled in the study. The research team intends to rollover the participants of our feasibility study into this current full randomized control trial comparing the efficacy outcome for the RithMM trial is the overall incidence of cardiovascular events, which includes arterial or venous thromboembolic events.

By conducting this trial, the investigators plan to externally validate the International Myeloma Working Group (IMWG) criteria model for thromboembolic risk by assessing the relevance of measuring pre-specified myeloma and thrombosis activity biomarkers (D-Dimer, beta-2 microglobulin, C-reactive protein (CRP), LDH) at every follow-up visit and their potential association with thromboembolism (TE) risk.

Study Timeline

• Study First Submitted: 2016-09-21
• Study First Submitted QC: 2018-02-08
• Study First Posted: 2018-02-09
• Study Start: 2019-01-17
• Primary Completion: 2023-12-01
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-28
• Last Update Posted: 2024-02-29
• Study Completion: 2024-09-30

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 57

Inclusion Criteria

1. Diagnosis of Multiple Myeloma

2. Scheduled to start on Len-Dex therapy

3. Be ≥ 18 years of age

4. Able to provide written informed consent

5. Pre-clinical laboratory must meet the following criteria at enrollment

   • Platelet count >50 × 109/L
   • Creatinine clearance (CrCl) >15mL/min using Cockcroft-Gault Equation

Exclusion Criteria

1. Major bleeding event within the previous 3 months prior to commencement of Len Dex therapy
2. Documented severe liver disease in the past 6 months (eg. acute clinical hepatitis, chronic active hepatitis, or cirrhosis)
3. Patient with a history of antiphospholipid syndrome especially if he/she is triple positive for lupus anticoagulant, anticardiolipin antibodies, and/or anti-b2 glycoprotein I antibodies.
4. A history of malignancy (with the exception of MM) within 2 years before randomization or any previously diagnosed malignancy with evidence of residual disease. Patients with a history of basal cell or squamous carcinoma are not excluded.
5. Patient with history of gastric or duodenal ulcer within 2 years
6. Plasma cell leukemia; systemic amyloidosis
7. Patient on therapeutic anticoagulation for treatment of VTE or ATE, or stroke prevention in non-valvular atrial fibrillation. Patients with a previous history of VTE who are not on any active anticoagulant therapy will not be excluded.
8. Patient on antiplatelet agents due to an absolute indication (e.g.; coronary stent, carotid stent).
9. Patients receiving concomitant systemic treatment with strong inhibitors of both CYP3A4 and P-gp such as ketoconazole, itraconazole, posaconazole or ritonavir)
10. Patient on single agent lenalidomide
11. Life expectancy less than 3 months as determined by the investigator.
12. Unstable medical or psychological condition that would interfere with trial participation, as determined by the investigator
13. Patient not able or not willing to give consent to participate in the study
14. Uncontrolled cardiovascular disease within 6 months prior to enrollment
15. Uncontrolled or poorly controlled diabetes or renal disease
16. Major surgery within 2 weeks before randomization
17. Known allergies, hypersensitivity, or intolerance to any of the study drugs.
18. Patients not able or not willing to give consent to participate in the Study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: FACTORIAL

Arm && Interventions

Group	Intervention	Description
Len-Dex+Rivaroxaban	Rivaroxaban	Patients with MM will receive Len-Dex combination and Rivaroxaban (10 mg) daily
Len-Dex+ASA	ASA	Patients MM will receive Len-Dex combination and ASA 81 mg daily

Primary Outcome Measures

Name	Time	Method
Incidence of venous thromboembolic (VTE) and/or arterial thromboembolic (ATE) events in patients with Multiple Myeloma placed on the Rivaroxaban vs Aspirin after starting with Len-Dex therapy	6 months	At each visit, patients will be asked standardized questions to capture the presence of primary. During these interviews the study coordinator will collect data related to resource utilization (e.g. health care services use) and ask whether the patient had a diagnosis of VTE, ATE or a bleeding event during this period. Any hospital or medical office encounters associated to any of the above-mentioned complaints will be checked and any test or procedures done will be recorded (e.g; echocardiogram, ECG, CT scan, MRI, transfusion).
Number of participants with treatment-related adverse events as assessed by CTCAE v6.0	6 months	Frequency and severity of adverse events and serious AEs based on hospital admission and patient-self reporting events

Secondary Outcome Measures

Name	Time	Method
External validation of the IMWG criteria for risk assessment of thromboembolic events in multiple myeloma patients	6 months	Subgroup analysis stratifying patients into low and high risk of thromboembolic events to assess any potential difference in the efficacy and safety outcomes.
Assessment of correlation of between levels of biomarkers of myeloma and thrombosis with the risk of ATE or VTE	6 months	The bio-markers are: D-dimer, LDH, B2 microglobulin and C-reactive protein (CRP) will be collected

Trial Locations

Locations (1)

London Health Sciences Centre; 🇨🇦 London, Ontario, Canada